<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Axsome Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/axsome-therapeutics-inc</link>
<description>Latest news and press releases for Axsome Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/axsome-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354a7c78dffbe2df0e4b1c.webp</url>
<title>Axsome Therapeutics Inc</title>
<link>https://6ix.com/company/axsome-therapeutics-inc</link>
</image>
<item>
<title>Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-to-report-first-quarter-2026-financial-results-on-may-4</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-to-report-first-quarter-2026-financial-results-on-may-4</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of</description>
</item>
<item>
<title>Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-acquires-selective-pde10a-inhibitor-balipodect-for-the-treatment-of-schizophrenia-and-other-neuropsychiatric-conditions</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-acquires-selective-pde10a-inhibitor-balipodect-for-the-treatment-of-schizophrenia-and-other-neuropsychiatric-conditions</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands</description>
</item>
<item>
<title>Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-initiates-clarity-phase-3-trial-of-solriamfetol-in-adults-with-major-depressive-disorder-with-excessive-daytime-sleepiness-symptoms</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-initiates-clarity-phase-3-trial-of-solriamfetol-in-adults-with-major-depressive-disorder-with-excessive-daytime-sleepiness-symptoms</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of</description>
</item>
<item>
<title>Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively,representing 65% and 66% year-over-year growth AUVELITY® 4Q</description>
</item>
<item>
<title>Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of</description>
</item>
<item>
<title>Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-settles-sunosi-solriamfetol-120000886</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-settles-sunosi-solriamfetol-120000886</guid>
<pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
<description>NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem) resolving patent litigation related to Axsome’s product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from sub</description>
</item>
<item>
<title>Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-report-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-report-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Tue, 27 Jan 2026 05:00:00 GMT</pubDate>
<description>NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of</description>
</item>
<item>
<title>Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-initiates-forward-phase-3-trial-axs-14-management-fibromyalgia</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-initiates-forward-phase-3-trial-axs-14-management-fibromyalgia</guid>
<pubDate>Thu, 15 Jan 2026 05:00:00 GMT</pubDate>
<description>NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of</description>
</item>
<item>
<title>Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-provides-preliminary-fourth-quarter-and-full-year-2025-net</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-provides-preliminary-fourth-quarter-and-full-year-2025-net</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth,</description>
</item>
<item>
<title>Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-announces-fda-acceptance-and-priority-review-supplemental-new</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-announces-fda-acceptance-and-priority-review-supplemental-new</guid>
<pubDate>Wed, 31 Dec 2025 05:00:00 GMT</pubDate>
<description>FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome</description>
</item>
<item>
<title>Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-announces-fda-pre-nda-meeting-minutes-axs-12-narcolepsy</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-announces-fda-pre-nda-meeting-minutes-axs-12-narcolepsy</guid>
<pubDate>Wed, 31 Dec 2025 05:00:00 GMT</pubDate>
<description>New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a</description>
</item>
<item>
<title>Axsome Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-participate-upcoming-investor-conferences-2025-11-20</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-participate-upcoming-investor-conferences-2025-11-20</guid>
<pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
<description>NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of</description>
</item>
<item>
<title>Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-acquires-subtype-selective-gaba-receptor-positive-allosteric</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-acquires-subtype-selective-gaba-receptor-positive-allosteric</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and</description>
</item>
<item>
<title>Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/avenue-therapeutics-announces-acquisition-of-subsidiary-baergic-bio-by-axsome-therapeutics-1</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/avenue-therapeutics-announces-acquisition-of-subsidiary-baergic-bio-by-axsome-therapeutics-1</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high</description>
</item>
<item>
<title>Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY® 3Q 2025 net product sales of $136.1 million,</description>
</item>
<item>
<title>Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-recognizes-mental-illness-awareness-week-along-national-advocacy</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-recognizes-mental-illness-awareness-week-along-national-advocacy</guid>
<pubDate>Thu, 09 Oct 2025 04:00:00 GMT</pubDate>
<description>NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of</description>
</item>
<item>
<title>Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-report-third-quarter-2025-financial-results-november-3-2025-10-07</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-report-third-quarter-2025-financial-results-november-3-2025-10-07</guid>
<pubDate>Tue, 07 Oct 2025 04:00:00 GMT</pubDate>
<description>NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of</description>
</item>
<item>
<title>Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-highlights-data-across-its-leading-neuroscience-pipeline-psych</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-highlights-data-across-its-leading-neuroscience-pipeline-psych</guid>
<pubDate>Wed, 17 Sep 2025 04:00:00 GMT</pubDate>
<description>Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep</description>
</item>
<item>
<title>Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-reports-second-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-reports-second-quarter-2025-financial-results-and-provides</guid>
<pubDate>Mon, 04 Aug 2025 04:00:00 GMT</pubDate>
<description>Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of</description>
</item>
<item>
<title>Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline</title>
<link>https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-hosts-frontiers-brain-health-rd-day-reviewing-industry-leading</link>
<guid isPermaLink="true">https://6ix.com/company/axsome-therapeutics-inc/news/axsome-therapeutics-hosts-frontiers-brain-health-rd-day-reviewing-industry-leading</guid>
<pubDate>Mon, 21 Jul 2025 04:00:00 GMT</pubDate>
<description>Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new</description>
</item>
</channel>
</rss>